Cite
HARVARD Citation
Crittenden, M. et al. (n.d.). Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas. Journal for immunotherapy of cancer. p. . [Online].